Validation of Biomarkers for Prostate Cancer Prognosis

2014 ◽  
Author(s):  
Ziding Feng ◽  
James D. Brooks
Keyword(s):  
Prostate Cancer ◽  
Cancer Prognosis ◽  
Prostate Cancer Prognosis

242: Variants of Semaphorin 3F are Associated with Prostate Cancer Prognosis

2006 ◽  
Vol 175 (4S) ◽  
pp. 80-80
Author(s):  
Timothy C. Brand ◽  
Dawn Garcia ◽  
Edith Canby-Hagino ◽  
Ian M. Thompson ◽  
Dean Troyer ◽  
...  
Keyword(s):  
Prostate Cancer ◽  
Cancer Prognosis ◽  
Semaphorin 3F ◽  
Prostate Cancer Prognosis

scholarly journals Prostate cancer prognosis after initiation of androgen deprivation therapy among statin users. A population-based cohort study

2021 ◽  
Author(s):  
A. I. Peltomaa ◽  
P. Raittinen ◽  
K. Talala ◽  
K. Taari ◽  
T. L. J. Tammela ◽  
...  
Keyword(s):  
Prostate Cancer ◽  
Androgen Deprivation Therapy ◽  
Cancer Prognosis ◽  
Cancer Death ◽  
Psa Relapse ◽  
Prostate Cancer Death ◽  
Study Population ◽  
Statin Use ◽  
Prostate Cancer Prognosis

Abstract Purpose Statins’ cholesterol-lowering efficacy is well-known. Recent epidemiological studies have found that inhibition of cholesterol synthesis may have beneficial effects on prostate cancer (PCa) patients, especially patients treated with androgen deprivation therapy (ADT). We evaluated statins’ effect on prostate cancer prognosis among patients treated with ADT. Materials and methods Our study population consisted of 8253 PCa patients detected among the study population of the Finnish randomized study of screening for prostate cancer. These were limited to 4428 men who initiated ADT during the follow-up. Cox proportional regression model adjusted for tumor clinical characteristics and comorbidities was used to estimate hazard ratios for risk of PSA relapse after ADT initiation and prostate cancer death. Results During the median follow-up of 6.3 years after the ADT initiation, there were 834 PCa deaths and 1565 PSA relapses in a study cohort. Statin use after ADT was associated with a decreased risk of PSA relapse (HR 0.73, 95% CI 0.65–0.82) and prostate cancer death (HR 0.82; 95% CI 0.69–0.96). In contrast, statin use defined with a one-year lag (HR 0.89, 95% CI 0.76–1.04), statin use before ADT initiation (HR 1.12, 95% CI 0.96–1.31), and use in the first year on ADT (HR 1.02, 95% CI 0.85–1.24) were not associated with prostate cancer death, without dose dependency. Conclusion Statin use after initiation of ADT, but not before, was associated with improved prostate cancer prognosis.

Polymorphisms in the glutathione S-transferase M 1 , T 1 , and P 1 genes and prostate cancer prognosis

The Prostate ◽  
2006 ◽  
Vol 66 (14) ◽  
pp. 1535-1541 ◽  
Author(s):  
Ilir Agalliu ◽  
Daniel W. Lin ◽  
Claudia A. Salinas ◽  
Ziding Feng ◽  
Janet L. Stanford
Keyword(s):  
Prostate Cancer ◽  
Cancer Prognosis ◽  
Glutathione S Transferase ◽  
Prostate Cancer Prognosis

Serum Vitamin D and Prostate Cancer Prognosis: The Story Continues

2016 ◽  
Vol 34 (30) ◽  
pp. 3709-3710 ◽  
Author(s):  
Elisa Roca ◽  
Francesca Valcamonico ◽  
Vito Amoroso ◽  
Alessandro Antonelli ◽  
Chiara Foroni ◽  
...  
Keyword(s):  
Prostate Cancer ◽  
Vitamin D ◽  
Serum Vitamin ◽  
Cancer Prognosis ◽  
Serum Vitamin D ◽  
Prostate Cancer Prognosis

Detectable biomarkers in urine for prostate cancer prognosis

2019 ◽  
Vol 18 (8) ◽  
pp. e3084
Author(s):  
S. Krossa ◽  
H. Bertilsson ◽  
T.F. Bathen ◽  
G.F. Giskeødegård ◽  
M.-B. Tessem
Keyword(s):  
Prostate Cancer ◽  
Cancer Prognosis ◽  
Prostate Cancer Prognosis
Sign in / Sign up

Export Citation Format

Share Document